International Journal of Hematology

, Volume 90, Issue 4, pp 446–454 | Cite as

Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

  • Jeanne M. Lusher
  • Inge Scharrer
Review Article


The use of factor VIII (FVIII) concentrates in the treatment of hemophilia A has raised important safety issues, historically of pathogen transmission and increasingly of inhibitor development to FVIII treatment. While manufacturing processes of current recombinant FVIII products have been shaped entirely around preventing pathogen transmission, the same modifications that afford a greater margin of safety could affect immunogenicity of the product, consequences of which could only be seen through long-term clinical experience. This review summarizes pathogen safety and inhibitor reports from clinical trials, post-marketing surveillance studies, and study reports on KOGENATE® and its successor, Kogenate® FS/Bayer. Although KOGENATE and Kogenate FS/Bayer are nearly identical products, subtle manufacturing improvements to address the need for greater margins of safety from a pathogen transmission perspective have also led to a potentially improved immunogenicity profile (15% in previously untreated/minimally treated patients with severe hemophilia A for Kogenate FS/Bayer). Notably, there has been no occurrence of pathogen contamination, and minimal de novo inhibitor formation in previously treated patients throughout the use of both products. Overall, KOGENATE and Kogenate FS/Bayer have a long history of safety in a variety of clinical settings, including treatment of bleeding, surgical management, and prophylaxis therapy.


Hemophilia FVIII Recombinant FVIII Inhibitors Pathogen safety 



The authors thank Bayer HealthCare for editorial support in the development of this manuscript.


  1. 1.
    Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006;367:252–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia. 2006;12:23–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Neugebauer B, Drai C, Haase M, Hilger A, Keller-Stanislawski B, Laitinen-Parkkonen P, et al. Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines. Haemophilia. 2008;14:142–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia. 2006;12:579–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost. 1997;77:80–6.PubMedGoogle Scholar
  6. 6.
    Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands Dutch Hemophilia Study Group. Blood. 1993;81:2180–6.PubMedGoogle Scholar
  7. 7.
    Lawn RM, Vehar GA. The molecular genetics of hemophilia. Sci Am. 1986;254:48–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Boedeker BG. Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost. 2001;27:385–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Gomperts E, Lundblad R, Adamson R. The manufacturing process of recombinant factor VIII, recombinate. Transfus Med Rev. 1992;6:247–51.CrossRefPubMedGoogle Scholar
  10. 10.
    (2007) Advate European Public Assessment Report Scientific Discussion. European Medicines Agency.Google Scholar
  11. 11.
    Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Dodd RY, Notari EPt, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion (Paris). 2002;42:975–9.CrossRefGoogle Scholar
  13. 13.
    Phelps R, Robbins K, Liberti T, Machuca A, Leparc G, Chamberland M, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion (Paris). 2004;44:929–33.CrossRefGoogle Scholar
  14. 14.
    Fiebig EW, Heldebrant CM, Smith RI, Conrad AJ, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr. 2005;39:133–7.PubMedGoogle Scholar
  15. 15.
    Chamberland ME. Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin Infect Dis. 2002;34:797–805.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee DC, Miller JLA, Petteway SR Jr. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE® Bayer. Haemophilia. 2002;8:6–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Jiang R, Monroe T, McRogers R, Larson PJ. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia. 2002;8(Suppl 2):1–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Cai K, Gierman TM, Hotta J, Stenland CJ, Lee DC, Pifat DY, et al. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens. BioDrugs. 2005;19:79–96.CrossRefPubMedGoogle Scholar
  19. 19.
    (2009) Kogenate Bayer product information. European Medicines Agency.Google Scholar
  20. 20.
    (2007) Kogenate Bayer variation application EMEA/H/C/275/II/30. European Medicines Agency.Google Scholar
  21. 21.
    Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma’s subsequent fractionation. Transfusion (Paris). 1990;30:591–8.CrossRefGoogle Scholar
  22. 22.
    Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion (Paris). 1985;25:516–22.CrossRefGoogle Scholar
  23. 23.
    Lee DC, Stenlanda CJ, Hartwella RC, Forda EK, Caia K, Millera JLC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods. 2000;84:77–89.CrossRefPubMedGoogle Scholar
  24. 24.
    Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, et al. Solvent-dependent precipitation of prion protein. Biochim Biophys Acta. 2002;1597:28–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion (Paris). 2001;41:449–55.CrossRefGoogle Scholar
  26. 26.
    Hematology/Cardiology GCDTA (2008) Periodic safety update report-antihemophilic factor (Recombinant) formulated with sucrose. Bayer Healthcare.Google Scholar
  27. 27.
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328:453–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost. 2004;2:574–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost. 1998;80:779–83.PubMedGoogle Scholar
  30. 30.
    White GC, DiMichele D, Mertens K, Negrier C, Peake IR, Prowse C, et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1999;81:462.PubMedGoogle Scholar
  31. 31.
    Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia. 1999;5:9–16.CrossRefPubMedGoogle Scholar
  32. 32.
    Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19:139–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93:457–67.PubMedGoogle Scholar
  35. 35.
    Norenberg C, Gorina E (2007) Statistical analysis plan for an integrated analysis of rFactor VIII (Kogenate FS). Bayer HealthCare AG.Google Scholar
  36. 36.
    Oldenburg J, Ivaskevicius V, Schroder J, Muller CR, Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost. 2006;95:903–5.PubMedGoogle Scholar
  37. 37.
    Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group. Thromb Haemost. 2000;83:811–6.PubMedGoogle Scholar
  38. 38.
    Yoshioka A, Fukutake K, Takamatsu J, Shirahata A. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data. Int J Hematol. 2006;84:158–65.CrossRefPubMedGoogle Scholar
  39. 39.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost. 2008;99:52–8.PubMedGoogle Scholar
  40. 40.
    Delumeau JC, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost. 2008;100:32–7.PubMedGoogle Scholar
  41. 41.
    Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia. 2008;14:281–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost. 2007;98:1188–92.PubMedGoogle Scholar
  43. 43.
    Maas-Enriquez M, Gorina E, Bajwa N, Lemm G. Inhibitor development in patients with hemophilia A treated with sucrose-formulated recombinant factor VIII. J Thromb Haemost. 2007;5(Suppl 2):P-T-138.Google Scholar
  44. 44.
    Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14:671–84.CrossRefPubMedGoogle Scholar
  45. 45.
    Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, et al. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia. 2000;6:614–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  1. 1.Hemophilia and Hemostasis ProgramChildren’s Hospital of MichiganDetroitUSA
  2. 2.University HospitalMainzGermany
  3. 3.Department of Hematology/OncologyJohannes Gutenberg-University MainzMainzGermany

Personalised recommendations